Q32 Bio Inc. announced that it has entered into agreement with existing and new investors for a private placement of $42 million November 16, 2023. The transaction included participation from new investors, Bristol-Myers Squibb Company, CU Healthcare Innovation Fund, L.P., managed by, University of Colorado School of Medicine, Endowment Arm, Agent Capital, returning investors, OrbiMed Advisors LLC, Atlas Venture L.P., Abingworth LLP, Acorn Bioventures, Oup Management Co., LLC, Sanofi Ventures and other undisclosed investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.19 USD | +5.18% | -0.77% | +148.45% |
04-11 | Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target | MT |
04-03 | Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
44.04 USD | +0.32% | +0.23% | 89.27B | ||
27.19 USD | +5.18% | -0.77% | 324M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+148.45% | 324M | |
+10.44% | 107B | |
+0.82% | 106B | |
+6.72% | 23.47B | |
-13.89% | 21.9B | |
-6.64% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- QTTB Stock
- News Q32 Bio Inc.
- Q32 Bio Inc. announced that it expects to receive $42 million in funding from a group of investors